早产儿早期抗生素使用的时间趋势与中心间差异
该回顾性队列研究利用美国297家学术与社区医院的住院管理数据库,纳入2009至2015年入住新生儿重症监护室且存活至少1天的极低出生体重儿(<1500 g)40364例(其中超低出生体重儿<1000 g共12947例),评估出生3天内起始抗生素及后续用药超过5天的比例。结果显示极低出生体重儿78.6%、超低出生体重儿87.0%早期起始抗生素,7年间时间趋势分析无显著变化(P=.12和P=.52);极低出生体重儿延长抗生素疗程比例随时间有小幅显著下降(P=.02),超低出生体重儿无显著变化(P=.22)。各中心早期抗生素暴露差异明显,61.1%(69/113)中心对超过75%的极低出生体重儿起始抗生素,84.8%(56/66)中心对超过75%的超低出生体重儿起始抗生素;延长抗生素比例在各中心间分别为0%至80.4%和0%至92.0%。作者认为中心间变异提示需开展新生儿抗菌药物管理以优化极低和超低出生体重儿的抗生素使用。
要点
- 极低出生体重儿(<1500 g)中78.6%(31715/40364)在出生3天内起始经验性抗生素,超低出生体重儿(<1000 g)中87.0%(11264/12947)早期起始。
- 2009至2015年早期抗生素起始比例无显著时间趋势变化(极低出生体重儿P=.12,超低出生体重儿P=.52)。
- 极低出生体重儿延长抗生素疗程(>5天)比例随时间有小幅显著下降(P=.02),超低出生体重儿无显著变化(P=.22)。
- 中心间差异大:61.1%(69/113)中心对超过75%的极低出生体重儿起始抗生素,84.8%(56/66)中心对超过75%的超低出生体重儿起始抗生素。
- 各中心延长抗生素比例范围分别为极低出生体重儿0%至80.4%、超低出生体重儿0%至92.0%,作者认为需开展新生儿抗菌药物管理。
适用人群与场景
- 美国297家学术与社区医院新生儿重症监护室收治的极低出生体重儿(<1500 g),包括超低出生体重儿(<1000 g),且存活至少1天。
研究设计与关键结果
- 研究类型为回顾性队列研究,利用美国297家学术与社区医院住院管理数据库,纳入2009至2015年极低出生体重儿40364例(女性20447例,50.7%),其中超低出生体重儿12947例。
- 暴露定义为出生3天内起始抗生素及后续抗生素使用超过5天。
- 极低出生体重儿早期抗生素起始比例为78.6%(31715/40364),超低出生体重儿为87.0%(11264/12947);时间趋势分析无显著变化(极低出生体重儿P=.12,超低出生体重儿P=.52)。
- 极低出生体重儿早期抗生素使用比例的年度风险差范围为-0.75%(95%CI,-1.61%至0.11%)至-0.87%(95%CI,-2.04%至0.30%);超低出生体重儿为-0.34%(95%CI,-1.28%至0.61%)至-0.38%(95%CI,-1.61%至0.85%)。
- 极低出生体重儿延长抗生素疗程比例随时间有小幅显著下降(P=.02),超低出生体重儿无显著变化(P=.22);极低出生体重儿延长疗程比例的年度风险差范围为-0.94%(95%CI,-1.65%至-0.23%)至-1.08%(95%CI,-2.00%至-0.16%);超低出生体重儿为-0.72%(95%CI,-1.83%至0.39%)至-0.75%(95%CI,-1.96%至0.46%)。
- 中心间变异:113家中心中69家(61.1%)对超过75%的极低出生体重儿起始抗生素;66家中心中56家(84.8%)对超过75%的超低出生体重儿起始抗生素;各中心延长抗生素比例范围分别为极低出生体重儿0%至80.4%、超低出生体重儿0%至92.0%。
证据类型、等级与局限
- 证据类型为回顾性队列研究,利用美国297家学术与社区医院的管理数据库。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,各中心间早期抗生素暴露的差异提示需开展新生儿抗菌药物管理以优化极低和超低出生体重儿的抗生素使用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Premature infants are frequently administered empirical antibiotic therapy at birth. Early and prolonged antibiotic exposures among infants without culture-confirmed infection have been associated with increased risk of adverse outcomes.
OBJECTIVE: To examine early antibiotic use among premature infants over time and across hospitals in the United States.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used a comprehensive administrative database of inpatient encounters from 297 academic and community hospitals across the United States to examine data concerning very low-birth-weight (VLBW) infants (<1500 g), including extremely low-birth-weight (ELBW) infants (<1000 g), who were admitted to the neonatal intensive care unit and survived for at least 1 day. Data collection took place in November 2015 and analysis took place from February 2016 to November 2016.
EXPOSURES: Antibiotic initiation within the first 3 days of age and subsequent antibiotic administration for more than 5 days.
MAIN OUTCOMES AND MEASURES: Temporal trends in early antibiotic initiation and duration from 2009 to 2015, and center variation in early antibiotic use from 2014 to 2015.
RESULTS: We identified 40 364 VLBW infants (20 447 female [50.7%]) who survived for at least 1 day, including 12 947 ELBW infants, from 297 centers. The majority of premature infants had early antibiotic initiation (31 715 VLBW infants [78.6%] and 11 264 ELBW infants [87.0%]), and no differences were observed over time in temporal trend analyses (P = .12 for VLBW and P = .52 for ELBW). The annual risk difference in the proportion of VLBW infants administered early antibiotic therapy ranged from -0.75% (95% CI, -1.61% to 0.11%) to -0.87% (95% CI, -2.04% to 0.30%); in ELBW infants the annual risk difference ranged from -0.34% (95% CI, -1.28% to 0.61%) to -0.38% (95% CI, -1.61% to 0.85%). There was a small but significant decrease over time in the rate of prolonged antibiotic duration for VLBW infants (P = .02), but not for ELBW infants (P = .22). The annual risk difference in the proportion of VLBW infants with prolonged antibiotic duration ranged from -0.94% (95% CI, -1.65% to -0.23%) to -1.08% (95% CI, -2.00% to -0.16%); in ELBW infants the annual risk difference ranged from -0.72% (95% CI, -1.83% to 0.39%) to -0.75% (95% CI, -1.96% to 0.46%). We also observed variation in early antibiotic exposures across centers. Sixty-nine of 113 centers (61.1%) started antibiotic therapy for more than 75% of VLBW infants, and 56 of 66 centers (84.8%) started antibiotic therapy for more than 75% of ELBW infants. The proportion of VLBW and ELBW infants administered prolonged antibiotics ranged from 0% to 80.4% and 0% to 92.0% across centers, respectively.
CONCLUSIONS AND RELEVANCE: Most premature infants in this study received empirical early antibiotic therapy with little change over a recent 7-year period. The variability in exposure rates across centers, however, suggests that neonatal antimicrobial stewardship efforts are warranted to optimize antibiotic use for VLBW and ELBW infants.
参考来源
- Flannery DD, Ross RK, Mukhopadhyay S, et al. Temporal Trends and Center Variation in Early Antibiotic Use Among Premature Infants. JAMA Netw Open. 2018. PMID: 30646054. doi:10.1001/jamanetworkopen.2018.0164
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。